To develop a novel treatment against lymphangioma applying signaling pathway for proliferation and survival of lymphatic endothelial cell

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K20304
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Pediatric surgery
• Research Institution: National Center for Child Health and Development (2016-2017); The University of Tokyo (2015)
• Principal Investigator: TAKAHASHI MASATAKA 国立研究開発法人国立成育医療研究センター, 細胞医療研究部, リサーチアソシエイト (10626766)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: リンパ管腫 / リンパ管奇形 / OK-432 / ブレオマイシン / ラパマイシン

Outline of Final Research Achievements

Lymphangioma is still a difficult disease to obtain satisfactory results. Surgical resection or sclerotherapy is the first choice for treatment. OK-432 and bleomycin have been used for sclerotherapy, and rapamycin for systemic therapy. OK-432 is well known to be one of the first line drugs for sclerotherapy, although it is not available in every country. Some cases are very effective to use OK-432. Although mechanism of action is unclear.
We established a method to obtain primary culture of human lymphangioma derived lymphatic endothelial cell (HL-LEC) from surgically resected tissue. It became a very good material for studying lymphangioma. The purpose of this study is to understand mechanism of several drug’s ,especially OK432’s, direct action against lymphangioma using HL-LEC in a condition without immune reaction. HL-LEC incorporates OK-432 and then dies. OK-432 particle remained after cell death. Microarray analysis showed OK-432 induced apoptosis for HL-LEC.

Free Research Field

小児外科